The use of the lidocaine-monoethylglycinexylidide test in the liver transplant recipient

Therapeutic Drug Monitoring

Volumn 18, Issue 4, 1996, Pages 383-387

  Potter, Julia M ^a,b   Hickman, Peter E ^a   Henderson, Alan ^a   Balderson, Glenda A ^a   Lynch, Steven V ^a   Strong, Russell W ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Hepatic artery thrombosis; Ischemia; Lidocaine; Monoethylglycinexylidide; Transplantation

Indexed keywords

DEETHYLLIDOCAINE; LIDOCAINE;

ADOLESCENT; ADULT; ANALYTIC METHOD; ARTERY THROMBOSIS; CHOLESTASIS; CONFERENCE PAPER; DRUG CLEARANCE; DRUG MONITORING; FEMALE; HUMAN; ISCHEMIA; LIVER BLOOD FLOW; LIVER FUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECIPIENT;

ADOLESCENT; ADULT; AGED; FEMALE; HEPATIC ARTERY; HUMANS; LIDOCAINE; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; THROMBOSIS;

EID: 0029833416     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199608000-00012     Document Type: Conference Paper

References (21)

1. Keefe EB. Selection of patients for liver transplantation. In: Maddrey WC, Sorrell MF, eds. Transplantation of the liver. 2nd ed. Norwalk, CT: Appleton & Lange, 1995:13-60.
2. Hickman PE, Lynch SV, Potter JM, Walker NI, Strong RW, Clouston AD. Gamma glutamyl transferase as a marker of liver transplant rejection. Transplantation 1994;57:1278-80.
3. Karayalcin K, Mirza DF, Harrison RF, et al. The role of dynamic and morphological studies in the assessment of potential liver donors. Transplantation 1994;57:1323-7.
4. Bargetzi MJ, Aoyama T, Gonzalez FJ, Meyer UA. Lidocaine metabolism in human liver microsomes by cytochrome P450-IIIA4. Clin Pharmacol Ther 1989;46:521-7.
5. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P450 III gene family as the major cyclosporine-metabolising enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988;43:630-5.
6. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992;20:753-61.
7. Potter JM, Hickman PE, Lynch SV, et al. Use of monoethylglycinexylidide as a liver function test in the liver transplant recipient. Transplantation 1993;56:1385-8.
8. Schutz E, Kaltefleiter M, Luy-Kaltefleiter M, et al. Prediction of early graft survival and complications by serial determination of MEGX and hyaluronic acid after OLT [Abstract]. Hepatology 1994;20:126A.
9. Oellerich M, Burdelski M, Ringe B, et al. Functional state of the donor liver and early outcome of transplantation. Transplant Proc 1991;23:1575-8.
10. Schroeder TJ, Gremse DA, Mansour ME, et al. Lidocaine metabolism as an index of liver function in hepatic transplant donors and recipients. Transplant Proc 1989;21: 2299-301.
11. Oellerich M, Burdelski M, Beyrau R, et al. Assessment of liver function in donors by use of the MEGX test. In: Brunner G, Mito M, eds. Advances in artificial liver support. Heidelberg: Springer-Verlag, 1992:132-9.
12. Mulligan MJ, Hawker F, Kam P. MEGX as a predictor of survival after liver transplantation [Abstract]. Anaesth Intensive Care 1995;23:240.
13. Jalan R, Plevris JN, Jalan AR, Finlayson NDC, Hayes PC. A pilot study of indocyanine green clearance as an early predictor of graft function. Transplantation 1994;58:196-200.
14. Potter JM, Wright M, Lynch SV, et al. Lignocaine metabolism and liver function testing in primary graft failure following orthotopic liver transplantation. Med J Aust 1993; 158:125-6.
15. Potter JM, Hickman PE, Chen Y, et al. MEGX in hepatic artery thrombosis and ischaemia following liver transplantation [Abstract]. Ther Drug Monit 1993;15:125.
16. Potter JM, Hickman PE, Chen Y, Scott C, Lynch SV, Strong R. Lignocaine metabolism as a test of liver function in liver transplant recipients. In: Miyai K, Kanno T, Ishikawa E, eds. Progress in clinical biochemistry. Amsterdam: Elsevier Science Publishers, 1992:1049-51.
17. Kawata S, Imai Y, Inada M, et al. Selective reduction of hepatic cytochrome P450 content in patients with intrahepatic cholestasis: a mechanism for impairment of microsomal drug oxidation. Gastroenterology 1987;92:299-303.
18. Lehmann U, Armstrong VW, Schütz E, Regel G, Pape D, Oellerich M. Monoethylglycinexylidide as an early predictor of posttraumatic multiple organ failure. Ther Drug Monit 1995;17:125-32.
19. Oellerich M, Burdelski M, Beyrau R, et al. Lidocaine metabolite formation as a measure of early post-transplant liver function [Abstract]. Hepatology 1989;10:625A.
20. Christians U, Kohlhaw K, Esselmann H, et al. The yin and yang of lidocaine and cyclosporine metabolism in liver graft recipients. Transplant Proc 1994;26:2827-8.
21. Cakaloglu Y, Tredger JM, Devlin J, Williams R. Importance of cytochrome P450IIIA activity in determining dosage and blood levels of FK506 and cyclosporine in liver transplant recipients. Hepatology 1994;20:309-16.